Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome ...Middle East

AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that the U.S Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct a Phase...

Hence then, the article about direct biologics announces fda acceptance of ind application for a phase i ii clinical trial studying exoflo for acute respiratory distress syndrome was published today ( Wednesday 14/07/2021 - 09:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome )

Also on site :

• Target’s 'Sturdy' $60 3-Drawer Rolling Storage Cabinet Is 'Perfect for Small Spaces'
• Spotify Users Can’t Sue Over Discovery Mode ‘Payola’ Accusations, Judge Says
• China’s self-driving truck leaders say AI breakthroughs won’t accelerate rollout — here’s why